For this reason a disappearing stent is searched for long time which will act as a scaffold only for the essential period of time after PCI. This is named as bioabsorbable stent, bioresorbable stent, bioresorbable vascular scaffold (BVS), bioresorbable vascular scaffolding device or disappearing stent in different literatures. When assessing bioresorbable scaffold (BRS) technology, there are important questions to be asked:
• How long a scaffold is essential for the prevention of vessel recoil?
• What is the optimal rate of degradation of scaffold material? Does it completely degrade? If so, at what time points?
• What happens to the degraded products?
• What is the vessel composition following complete degradation?
• Are there any safety concerns?
• Are there any potential utility advantages of BRS over permanent metal stents? Will BRS ever be the workhorse stent to replace bestin-class DES?
First bioabsorbable stent, the Igaki-Tamai stent was implanted in human coronary arteries in 1999. Since then a number of bioabsorbable stent has been tried. There are challenges in making a stent that has sufficient radial strength for an appropriate duration, which does not have unduly thick struts, which can be a drug delivery vehicle, and where degradation does not generate an unacceptable inflammatory response. We will review different bioabsorbable stents those have been studied clinically.
The motivation for the development of bioabsorbable stents was driven by the need to solve the limitations of metallic stents, such as stent thrombosis, which requires prolonged antiplatelet therapy along with the risk of bleeding; mismatch of the stent to the vessel size, which often results in a smaller lumen after stent implantation; and artifacts with modern imaging technologies such as magnetic resonance imaging (MRI) and multi-slice computerized tomography (MSCT). Other potential limitations of metallic stents are impairment of vessel geometry and often jailing of side braches. Further, metallic stents prevent the lumen expansion associated with late favorable remodeling and vessel reactivity at the stented site. 2 Finally, excessive use of stents in the coronary vasculature (full metal jacket) may interfere with traditional re-interventional techniques such as bypass graft surgery.
These lead to the necessity of development of bioabsorbable stents that will leave behind only the healed, natural vessel allowing restoration of vasoreactivity with the potential for vessel remodeling. Because of their ability to exist for a short period of time and healing the diseased, stenosed vessel to a normal one, PCI with bioabsorbable stent is also termed as vascular scaffold therapy (VST) or vascular reparative therapy (VRT).
Goals of VRT:
If with advancement of technology proper bioabsorbable stents are made available many disadvantages of metallic stents can be avoided.
Unlike with permanent metallic stenting, the BVS will potentially allow future surgical revascularization, expansive remodeling, restoration of reactive vasomotion, and noninvasive imaging of coronary arteries with multislice computed tomography (MSCT). Given their temporary presence, the potential risk of late or very late stent thrombosis may be reduced or even eliminated.
prevention of acute and late recoil of blood vessels.
3. Most of the biodegradable materials available are radiolucent, so not visible by angiography. So their proper implantation needs further imaging technique like optical coherence tomography (OCT), which needs more hardware and expertise.
4. To prevent neoinitimal growth thus restenosis anti proliferative agents should be added to it. That means another vehicle material should be added to it. The degradation rate and the elution rate of drugs should be matched perfectly to prevent any untoward effects.
5. The end products of the polymer and the metal need to be addressed regarding whether they will reabsorb over time without creating systemic or local vessel toxicity and the preservation of the biocompatability with endothelial coverage and function.
How long vascular scaffold is needed
Stents scaffold intimal flaps that have been separated from deeper layers during angioplasty, prevent early constrictive remodeling, and deliver antiproliferative drug to limit excessive healing of injured vessel. This support is essential during the initial months after the procedure. After this, a permanent implant is unnecessary and has potential disadvantages.
But how long a stent is needed to prevent vascular recoil and constrictive remodeling is not clearly defined. In a cohort of patients consecutively recatheterized at 1, 2, 3, and 4 months, Serruys et al 3 demonstrated that the restenotic process after balloon angioplasty ceases to progress after 4 months. It is possible that after this time, scaffolding is no longer needed.
The poly-L-Lactide acid (PLLA) made non-drugeluting Igaki-Tamai device and drug eluting ABSORB stent did not show bioresorption of the polymeric struts at 6 months and this absence of ultrasonic changes in struts was parallel to the absence of scaffold shrinkage. This device presented a target vessel revascularization of 6.7% at 6 months and a low rate of major cardiac events at 10 years. 4, 5 Conversely, the PROGRESS-AMS magnesium platform nondrug-eluting bioresorbable scaffold had a rapid resorption which was complete at 4-month follow-up. This swift resorption produced an important reduction of the lumen (60% of the late lumen loss) and a high incidence of restenosis (47.5% assessed by quantitative coronary angiography (QCA). 6 The REVA device is a poly (iodinated desaminotyrosyltyrosine ethyl ester) carbonate non-drug-eluting scaffold. The closed design and the lifecycle of the carbonate provide enough radial strength during the first 3 months following the implantation without appreciable shrinkage. However, focal mechanical failures driven by polymer embrittlement led to a high rate of target lesion revascularization (TLR) (66.7%) between 4-and 6-month follow-up. 7 ABSORB 1.0, ABSORB 1.1 and the Magnesium stent used in BIOSOLVE-I trial provided their scaffold function for at least 6 months. Though they are drug eluting stents their structural integrity upto six months reduced the late recoil and constrictive remodeling of blood vessel. Even the slower degradation of ABSORB 1.1 over ABSORB 1.0 was also of benefit in prevention of late recoil.
So for any bioabsorbable stent it should provide a good mechanical support for 6 months and then disappear.
Materials for bioabsorbable stent
Currently, there are number of materials being tried for bioabsorbable scaffolds, of which lactide polymers, particularly PLLA, form the basis of several devices and are the most extensively investigated. Other materials include magnesium, polyanhydrides (salicylic acid and adipic acid) and polycarbonates (amino acids, eg, tyrosine).
Life cycle of PLLA
The poly-L-lactic acid (PLLA) has a lifecycle which can be divided in five phases. 8 First, immediately after the deployment, the polymer absorbs water from blood and surrounding tissues. Second, the long chains of PLLA degrade by hydrolysis into smaller chains without affecting the device's structure. Third, the hydrolysis process continues and causes a loss in integrity, with fragmentation of the struts and loss of radial strength. Fourth, soluble monomeric anions dissolve into the intercellular fluid and microparticles of less than 2 mm may be phagocytosed by the macrophages; manifesting in mass loss and bioresorption. Finally, the soluble L-lactate is converted into pyruvate, which enters the Krebs cycle, being eventually converted into carbon dioxide and water. The initial degradation process of the PLLA semi-crystalline polymer depends on the length of the polymers chain (molecular weight), the hydrophilicity, and the degree of crystallinitiy. The duration of the degradation process varies from 2 to 4 years.
of-phase zigzag hoops linked together by three longitudinal bridges between each hoop. The BVS 1.0 design is shown in Figure 3 . In ABSORB clinical trial (cohort A), despite the impressive clinical outcomes, that were comparable with the XIENCE V® everolimus eluting stent (Abbott Vascular, Santa Clara, CA, USA), the ABSORB 1.0 device had a slightly higher, but insignificant acute and late recoil. There was a trend for more recoil when fewer struts were present. These observations prompted design modifications in order to reduce the maximum circular unsupported cross sectional area (MCUSA), increase radial force, and prolong the time for which the implant scaffolds the vessel, without changing the implant's total absorption time.
The manufacturing process of the ABSORB 1.1 (Abbott Vascular, Santa Clara, CA, USA) has been modified to enhance the mechanical strength and mechanical durability of the struts. Moreover, the new design has in-phase zigzag hoops linked by bridges that allow for a more uniform strut distribution, reduce MCUSA, and provide more uniform vessel wall support and drug transfer. 10 The polymer mass, coating content, amount of drug, and the strut thickness remain the same. This change in design leads to slower degradation of the scaffold and slower release of drugs. An OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial by Okamura et al showed that the new design has a reduced maximum circular unsupported cross sectional area. This change in design resulted in reduced late shrinkage and neointimal response with BVS 1.1. 10 The actual duration of resorption of the second generation in vivo is approximately 18 months longer than that of the first generation, and the mass loss of the second-generation ABSORB scaffold takes approximately 36 months.
At 6-month follow-up, patients treated with the ABSORB 1.0 had a significant decrease in minimum luminal diameter (MLD) (angiographic late loss) of 0.43 mm (p = 0.01), whereas a nonsignificant 0.08 mm decrease was seen in those treated with the BVS 1.1. The difference in late loss between the BVS 1.0 and 1.1, although numerically appreciable, failed to reach statistical significance at 6 months (P = 0.07). 11 
Vascular compliance and BVS:
From a mechanical perspective, stenting the coronary artery may locally stiffen the artery by reducing its compliance and creating a mismatch in compliance with respect to the The bioresorbable vascular scaffold system theoretically has many advantages over rigid metallic stents. In particular, because the scaffold is completely made of poly-lactide, it does not have the same stiffness as metal, thereby having the potential to overcome in part the problems related to local stiffening of the artery and compliance mismatch associated with metallic platform stents. In addition, the mismatch in compliance after scaffold implantation may potentially disappear in the long term once the scaffold is completely bioresorbed.In the study involving 83 patients of ABSORB trial, Brugaletta et al have shown that (1) scaffolding of a diseased vessel wall by an ABSORB BVS significantly reduces its compliance, with the compliance of the segment immediately distal to the device tending also to be reduced; (2) the mismatch in compliance that 12 This mismatch may eventually provoke flow disturbances and wall shear stress alterations with subsequent blood stasis ( Figure 4 ). 14 The wall shear stress distribution in a stented artery has been reported as a determinant factor for cellular growth and the occurrence of thrombus formation. 15 is present immediately after scaffold implantation disappears in the short-to midterm. 16 
BVS and vascular geometry
Stiff metallic stents can alter vessel geometry and biomechanics leading to long-term flow disturbances and chronic irritation producing adverse events. This change in vessel biomechanics is also responsible for late strut fractures, that could lead to restenosis and clinical events. 17, 18 After metallic stent implantation, the curvature of target vessel is increased by 121% at the entrance and by 100% at the exit of the stent, resulting in local changes in shear stress correlated with the local curvature. The initial superior conformability and flexibility of the ABSORB with respect to metallic stents can, at an early stage, contribute to less change in vessel geometry and biomechanics. 18 A retrospective study compares 102 patients who received a metallic stent (Multi-link Vision or Xience V) in the SPIRIT FIRST and II trials with 89 patients treated with the ABSORB Revision 1.1 everolimus-eluting BVS from cohort B of the ABSORB trial. Both the metallic stent (MPS) and BVS groups had significant changes in relative region curvature (MPS vs.BVS: 28.7% vs. 7.5%) and angulation (MPS vs. BVS: 25.4% vs. 13.4%) after deployment. The unadjusted comparisons between the 2 groups showed, for BVS a nonsignificant trend for less change in region curvature after deployment and a significantly lower modification of angulation. By multivariate regression analysis, the independent predictors of changes in curvature and angulation were the pretreatment region curvature, the pre-treatment region angulation, and the used device. 18 At 6-or 12-month followup, the anatomical configuration of the arteries treated with the ABSORB BVS allowed restoration of coronary geometry to values close to those measured before implantation. 19 Late vascular remodeling in metallic stent and BVS One possible fate of the dilated but caged lesion is an intra-stent lumen reduction by intra-stent neointimal tissue growth (negative remodeling), even if the cytostatic drug slows down or postpones the phenomenon. But in many of the cases there is retraction of the surrounding vessel wall from the metallic cage. This generates a late acquired malapposition. It has been demonstrated that a large malapposition at baseline will also persist at long term. Late and very late stent thrombosis has been associated with late malapposition, either acquired or persistent. 20 But in case of BVS, as the scaffold disappears, there is no chance of this late malposition and thus the chance of late and very late thrombosis is absent.
In case of BVS critical observation made by IVUS between 6-month and 2-year follow-up was a late luminal enlargement (10.9%) with significant plaque media reduction (12.7%) and without significant change in the vessel wall area (EEM). Still today, it is unknown whether this 'plaque media regression' on IVUS is a true atherosclerotic regression, with change in vessel wall composition and plaque morphology (from thin-cap atheroma to thick-cap atheroma) or a pseudo-regression due to bioresorption of the polymeric struts. 21
Imaging of BVS (ABSORB stent)
BVS is a radiolucent stent. So under fluoroscopy they are detected by the presence to two platinum markers on either side. The ultrasonic and light wave beams from the gray-scale intravascular ultrasound (GS-IVUS) and OCT catheters are backscattered in different ways from the polymeric structures as compared with metallic structures. Consequently, GS-IVUS and OCT render the BVS structures differently compared with metallic stents.
GS-IVUS imaging, with a 20 MHz catheter, renders the polymeric struts as hyper-refractive boxes with an important echogenic blooming effect that confers a double strut appearance. The polymeric struts have an echogenic intensity similar to calcium tissue, but without acoustic shadowing behind the struts (Fig. 5) . OCT shows the polymeric struts as a black central core surrounded by a light-scattering frame. The four sides of the polymeric struts are clearly visible without the typical shadowing observed behind metallic structures. In a substudy of ABSORB cohort B trial involving 48 patients, it was shown that GS-IVUS has a poor capacity to detect qualitative findings post-BVS implantation and its reproducibility is low compared with OCT. The use of GS-IVUS should be limited when assessing lumen and scaffold areas. 22 Bioabsorbable 23 It is because of the fact that the 2.5 mm ABSORB is actually the same device as the 3.0 mm device but crimped onto a smaller balloon, the deployment of a 3.0 mm ABSORB in small vessels (<2.5 mm) did not compromise safety. But implantation of ABSORB stent in an oversized vessel will lead to strut fracture and spontaneous Incomplete Stent Apposition (ISA) immediately after deployment, which may lead to stent thrombosis.
Technical aspects of BVS (ABSORB) implantation-
At present ABSORB BVS 1.1 is available in limited number of sizes. So appropriate sizing is mandatory. In ABSORB cohort B and ABSORB EXTEND Single Arm Study, vessel diameter was assessed by QCA and IVUS. Maximum diameter of the vessel measured by QCA proximal and distal to the lesion helped in appropriate sizing of the stents. 24 In ABSORB II trial stents with 2.5 mm diameter was used for the Dmax > 2.25 mm to d" 3.0 mm; 3.0 mm diameter stents for e" 2.5 to d" 3.3 mm and 3.5 mm stents for e" 3.0 to <3.8 mm.
Pre-dilatation prior to BVS implantation is mandatory. Post-dilatation with a balloon shorter than the implanted scaffold is at the operator's discretion. But overinflation has got a chance of strut fracture. As the ABSORB stents are radiolucent the stent should be detected by the platinum markers located on either side of the stent. Appropriateness of implantation should be evaluated by OCT.
All patients should be pre-treated with aspirin and a loading dose of at least 300 mg of clopidogrel. In ABSORB cohort B trial 101 patients were included and followed up for three years. ABSORB 1.1 stents were used in this trial. During the three-year follow-up period, there were no possible, probable, or definite scaffold thromboses. There were three non-Q-wave myocardial infarctions and seven ischaemia driven-TLRs, which resulted in a three-year MACE rate of 10%. QCA was done at 6,12,24 and 36 months. There were six in-segment restenoses at three years with a binary restenosis rate of 6%. 27 A non-randomized comparison of clinical outcomes of the Absorb BVS scaffold and the XIENCE V metallic stent was done involving the patients in ABSORB and SPIRIT trial. It shows that these two devices have possibly similar event rates up to three years. 27 The assessment of 'real world' treatment of de novo coronary artery disease with the Revision 1.1 BVS has begun in the ABSORB EXTEND multinational continued access trial, and interim data for the first 585 patients enrolled were presented. Of the first 500 patients there was a 97% procedural success, 0.6% TLR and 3.0% MACE rate at 6 months. 28 Furthermore, 250 patients have 12 months' follow-up clinical data with a 2.0% TLR and 4.4% MACE rate (comparable to the pooled SPIRIT trials event rate of 6.1%). 29 The ABSORB II trial is planned to be powered for non-inferiority versus the Xience V DES. Patient characteristics and angiographic characteristics are similar to the previous trials, except lesions upto 48 mm length will be included in the study. Lesions with proximal or distal Dmax of 2.25 to 3.8 mm will be included in the study. ABSORB BVS 1.1 stents with 2.5, 3.0 and 3.5 mm diameter will be used. Exclusion criteria are same like the previous trials. Clinical follow-up is planned at 30 and 180 days and at 1, 2, and 3 years. All subjects will undergo coronary angiography, IVUS and IVUS-virtual histology at baseline (pre-device and post-device implantation) and at 2-year angiographic followup. The primary end point is superiority of the Absorb BVS vs. XIENCE stent in terms of vasomotor reactivity of the treated segment at 2 years. The coprimary end point is the 
Small side branch occlusion and BVS (ABSORB stent)
A post hoc analysis of ABSORB Extend trial was done to evaluate the incidence and clinical consequence of small side branch occlusion (SBO). The data from ABSORB Extend was compared with those of SPIRIT trial using Everolimus Eluting Stent (EES). Increased but statistically insignificant amount of postprocedural SBO was observed in BVS group (6.0% vs. 4.1%. p=0.09). Patients with post-procedural SBO were significantly associated with an increased incidence of in-hospital myocardial infarction. Increased strut thickness was probably responsible for this increased incidence of SBO in BVS. 31 
BVS and myocardial bridge:
In the ABSORB cohort B2, two patients with a myocardial bridge have been included. One patient had an ischemia driven -TLR at three months. The second patient had aggravation of late loss from one year (0.96 mm) to three years (1.22 mm). Authors concluded that it would be prudent to consider myocardial bridging as a contraindication for treatment with a bioresorbable scaffold. 27 
BVS in chronic total occlusion (CTO)
CTOs were not included in the ABSORB trials. Some operators reported implantation of BVS in CTO lesions, but it needs long term study to evaluate whether it will be effective and safe in CTO lesion. 32 
BVS in small vessel
In ABSORB cohort B trial 41 patients had vessel diameter of < 2. 5 mm and 60 patients had vessel diameter of e" 2.5 mm. At 2-year angiographic follow-up no differences in late lumen loss, and in-segment binary restenosis were demonstrated between groups. In the small-vessel group, IVUS analysis showed a significant increase in vessel area, scaffold area and lumen area between 6-months and 2-year follow-up. No differences in plaque composition were reported between groups at either time point. At 2-year clinical follow-up, no differences in ischaemia-driven major adverse cardiac events, myocardial infarction or ischaemia-driven target lesion revascularization were reported between small and large vessels. No deaths or scaffold thrombosis were observed. 33 Overlapping BVS stents ABSORB stents are available in three different sizes 12,18 and 28 mm. In real time practice long lesions are to be dealt. Besides this when an edge dissection develops a second stent is always needed. In ABSORB trials long lesions were avoided, though in ABSORB extend SAS trial up to 28 mm lesions and in ABSORB II up to 48mm lesions are being dealt. So the experience with overlapping of the ABSORB stents is still waiting. Some individual case reports of using overlapping have been reported. The major difficulty is the strut size (150µ) of the stent. The delivery technique of two high profile stents will be difficult. The absorption kinetic and drug elution technique in case of overlapping stents is not well established. We have to wait for future trials to establish the fact. Some better design with a more low profile stent might allow us to deal this sort of complex lesions. 37 A study involving 41 overlapping ABSORB stents in pig has demonstrated that overlapping struts gives rise more neointimal response. At 28 days strut coverage was 79% in case of ABSORB and 99.6% in case Xience V. But at 90 days it was >99% in both the stent groups. Increased strut thickness was probably responsible for this delayed strut coverage. 38
BVS in calcified lesion

Absorbable metallic stent:
Absorbable metal stents (AMS) were designed to overcome drawbacks of BMS and DES. The idea was that AMS will provide the scaffolding support to the coronary arteries for the initial period of time after PCI, and then it will disappear. It will also be superior to PLLA scaffolds by providing better apposition to the vessel wall and can also be used in complex lesions like calcified lesions and chronic total occlusions. Two different metals have been triedi) magnesium alloy, ii) stainless steel. Stainless steel takes about 4 years to absorb and it was not tried that much.
Biodegradable magnesium stent:
The first metallic bioabsorbable stent implanted in humans is the magnesium alloy stent. It is balloon expandable, with strut thickness of 165 µm, and the 3-mm stent has a crossing profile of 1.2 mm compatible with a 6F guide catheter. The coverage of arterial wall by the expanded stent is similar to that of the conventional metallic stents (10%). 39 The radial strength at implantation is similar to that of stainless steel stents. 10 The stent is radiolucent.
The PROGRESS-AMS was a prospective, multicenter clinical trial of 63 patients with coronary artery disease who underwent PCI with Absorbable Magnesium Stent (AMS) implantation. This study demonstrated that biodegradable magnesium stents can be implanted safely and that the stents degraded as intended without stent thrombosis, myocardial infarction, or death at 1 year. 40 However, the study was associated with high angiographic restenosis rates of in-stent diameter stenosis (DS) (48.2 ± 17.0%) and insegment late loss (0.83 ± 0.51 mm), which led to ischemic-driven target lesion revascularization of 23.8% at 4 months and 27.9% at 1 year. Intravascular ultrasound imaging supported the degradation of AMS at 4 months. They concluded that slower degradation is needed to provide sufficient radial force to improve long-term patency rates of the AMS. 41 To overcome these drawbacks a drug-eluting absorbable metal scaffold (DREAMS; Biotronik, Bülach, Switzerland) is being tried. DREAMS was optimized to provide a longer scaffolding time than its predecessor and drug elution for inhibition of cell proliferation. The absorption process is complete after 9-12 months. The scaffold strut surface is coated with a 1 ¼m matrix of the absorbable polymer carrier polylactic-coglycolic acid and the antiproliferative drug paclitaxel. 42 BIOSOLVE-I was a prospective, non-randomized, multicentre, first-in-man trial to assess the safety and performance of a paclitaxel-eluting absorbable magnesium scaffold (DREAMS) in symptomatic patients with de-novo coronary lesions. The study was done at 5 centers in Europe. The study included 46 patients with 47 lesions. 12 patients had Type I lesion, 31 had Type IIa lesions and 4 had Type IIb lesions. Seven patients had moderate to severely calcified lesions. Patients were followed up for 36 months. At 12 months, 3 patients developed target lesion failure (7%). In-scaffold late lumen loss was 0.65 mm at 6 months and 0.52 mm at 12 months. It was better than AMS in PROGRESS study, but inferior to DES and ABSORB stent.
Implantation of the bioabsorbable everolimus eluting coronary scaffold system necessitated bailout stenting in 5·3% of the lesions, but DREAMS had a 100% procedural and device success rate. They concluded that the results of BIOSOLVE -1 with DREAM stent were noninferior to those with DES and ABSORB stents in most aspects. But further iterations of the device will need to be designed to reduce late lumen loss. 43 The Igaki-Tamai stent The Igaki-Tamai stent (Igaki Medical Planning Company, Kyoto, Japan), the first absorbable stent implanted in humans, is constructed from PLLA. Strut thickness is larger than that in contemporary metallic stents at 170 µm, and vessel coverage by stent struts (24%) is greater than that with contemporary metallic stents. This balloon-mounted self-expanding sheathed system where expansion is hastened by dilatation with warmed contrast medium (80 0 C) is cumbersome to use. As PLLA is radiolucent, gold markers at each end provide radio-opacity for stent identification. The stent does not release an antiproliferative drug. Stent struts retain shape until absorption is well advanced. In the preliminary, first-in-man prospective, nonrandomized clinical trial that enrolled 50 patients, a 4-year follow-up of all the patients (100%) revealed a low complication rate with one in-hospital stent thrombosis causing a Q-wave myocardial infarction, one noncardiac death, and 18% repeat PCI and no surgical revascularization. 4 Nishio et al report beyond 10 years' clinical outcome of the first 50 patients with coronary artery disease who were treated with 84 IgakiTamai stents. Restenosis rates are similar to those reported with bare metal stents. But the artery restored its capability to respond to positive remodeling once the scaffold degraded. 44 Newer PLLA based stents DeSolve (Elixir Medical Corporation, Sunnyvale,California) is a new PLLA based stent with strut thickness of 150 µm. The scaffold is coated with a matrix of polylactide-based polymer and myolimus at a 3 mg/mm dose; more than 85% of the drug is released over 4 weeks. The system has a crossing profile of 1.47 mm and is 6-F catheter compatible. This new device provides good radial strength for 4 months. And complete resorption of the scaffold occurs by 1 year. It has got the ability to self-correct to the vessel wall in cases of minor malapposition when expanded to the nominal diameter, which is accomplished using a proprietary processing technique. DeSolve stent has a wide safety margin for expansion where a 3.0-mm scaffold can be expanded to 4.5 mm in diameter without strut fracture.
A human trial using DeSolve stent was done in 16 patients showing good short and midterm results (upto 12 months) similar to ABSORB stents. The advantage of DeSolve stent over ABSORB stent is its early resorption without hampering the early or late lumen loss. So there is early anatomical and physiological normalization of blood vessels. Its ability to selfcorrect to the vessel wall in cases of early malapposition also gives an extra advantage. 45 The REVA device The REVA bioabsorbable scaffold is a tyrosinederived polycarbonate polymer device impregnated with iodine for radio-opacity. Initial FIM clinical trials (n=27) reported high clinical event rates (TLR 67%) attributed to focal mechanical failures of the device. 46 This device has been redesigned, resulting in the new ReZolve device (with a stronger polymer, sirolimus drug coating, and a novel slide and spiral lock mechanism). Clinical evaluation of this device began in December 2011 (RESTORE trial) and preliminary safety and performance data demonstrated 100% clinical procedural success rate and zero MACE events at 3 months (n=22). 47 However, this device has a sheathed delivery mechanism, limiting its use in small or tortuous vessels. Therefore, further development has resulted in the new ReZolve2 device, which has a lower prolife (6F), and a sheathless delivery system with an enhanced polymer, yielding a 30%
The IDEAL device This device has a polylactide anhydrite and salicylic acid-sebacic acid-salicylic acid trimer polymer backbone providing mechanical scaffolding, and a salicylic acid-adipic acidsalicylic acid trimer with sirolimus coating layer. The additional elution of salicylic acid has been shown to reduce inflammation in animal studies and may infer an advantage over 'conventional' polymers. The safety of the first generation IDEAL device (Bioabsorbable Technology, California, USA) was confirmed in the Whisper trial (n=11) with no early recoil. However, there was significant neointimal growth.
The second generation IDEAL BioStent (Xenogenics Corp, Massachusetts, USA) has an optimized scaffold design, higher drug dosage, slower drug release and alternations in delivery mechanisms conferring a reduction to 6F compatibility. Preclinical data are awaited for this iteration. 49 Future of BVS DES is a major breakthrough in interventional cardiology because they reduced the need for repeat intervention compared with BMS by more than 50%. Late (6 month to 1 year) or very late (beyond 1 year) thrombosis is the feared complication of DES that may result in myocardial infarction and death. A worst case scenario is that the problem of late-stent thrombosis after first-generation DES implantation may be ongoing indefinitely as a registry of 8000 patients reported that it occurred at a constant rate of 0.6% per annum without diminution by 4 years. 50 Indefinite continuation of dual antiplatelet therapy is not a practical solution because of expense and because a quarter of late-stent thromboses occurred in patients receiving dual antiplatelet therapy. 52 In addition, dual antiplatelet therapy may be discontinued because of troublesome minor bleeding or to reduce the risk of bleeding during surgery.
An ideal stent will be one which will give the scaffold action for the appropriate time period, will carry antiproliferative drug to prevent neointimal growth and will disappear thereafter. Bioabsorbable drug eluting stents are a great hope as this group of ideal stents.
Despite its initial promise, BVS technology has major challenges. By its nature, the plastic PLLA polymer is limited in expansion and optimal scaffold apposition. Overexpansion of the scaffold may result in fractures that can lead to target vessel failure. Furthermore, it is not clear how the PLLA scaffold will behave in calcified lesions, bifurcations, long lesions, or when overlapping of additional PLLA scaffolds is required.
In addition, the optimal duration of dualantiplatelet therapy with PLLA is unknown, but complete degradation duration of 3 years raises the question regarding the duration of dualantiplatelet therapy. Finally, manufacturing the PLLA BVS is complex, and the availability of a broad spectrum of vessel sizes and lesion lengths is currently limited. The question is whether PLLA limitations and the additional cost to patients will prevent the ABSORB device from becoming a workhorse in the treatment of coronary artery disease and ultimately replace permanent metal DES.
If an appropriate BVS is available along with the favorable answers to the above questions, it will be able to replace conventional metallic stents. It will reduce late and very late stent thrombosis, so there will be reduced use of antiplatelet agents. Physiologically, the absence of a rigid metallic cage will facilitate the restoration of the vessel vasomotor tone, adaptive shear stress, late luminal enlargement, and late expansive remodeling. In the long term, BVS will not hamper future treatment options such as PCI, CABG, or pharmacologically induced plaque regression. Furthermore, BVS will obviate some of the other problems associated with the use of permanent metallic stents such as the covering of side branches. It will also appear to be suitable for non-invasive imaging such as computed tomographic angiography or magnetic resonance imaging, due to the absence of artifact caused by permanent metallic materials.
Conclusion:
Potential advantage of having the stent disappear from the treated site is that it will change a diseased coronary artery to normal or near normal artery. Bioabsorbable stents have a potential pediatric role because they allow vessel growth and do not need eventual surgical removal. Considerable improvement has been done in the technology of Biodegradable stents. In case of Magnesium stents further improvement is needed to reduce the late lumen loss. For the PLLA stents, efforts needed to optimize scaffold radial force and expansion without early fractures. Trials should be carried out to define the role of biodegradable stents in more complex lesions like long lesions, calcified lesions, bifurcation lesions, left main lesions, ostial lesions etc. Also its efficacy should be verified in different clinical situations. How does it behave in overlapping conditions is also a concern. How the restenotic lesions of biodegradable stents should be managed is yet to be learned. And of course we should know how long the antiplatelets should be prescribed. Cost of these stents is also a concern. If we get the answers of these questions in a favorable way, only then we will be able to replace the BMS and DES with biodegradable stents. May be at that time we will look back and laugh at the days when we left a permanent metal stent in our patients' coronary arteries.
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